Pfizer (PFE)

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief international commercial officer and executive vice president. Speaking with Chris Schott at a company event

These companies are committed to rewarding shareholders.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Both are high-growth bets on unproven cutting-edge technologies.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Pfizer's rebound is well underway.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Pfizer has a history of developing treatments that generate billions in sales.

They have a knack for increasing their dividends even when facing challenges.

I'd buy Energy Transfer and Verizon stocks, and avoid Pfizer.

Income investors shouldn't be too worried about the pharma giant cutting its dividend.

The company is still looking to bounce back after the beating it took in recent years.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

IP Group (LON:IPO) reported higher net asset value, strong cash realizations and broad portfolio activity in the first half of 2026, while management said it remains focused on converting portfolio value into shareholder returns. Net asset value per share increased 3.2% during the half year to 114p

Analysts think Alnylam could rebound strongly over the next 12 months.

Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining COVID-19-related demand and upcoming losses of exclusivity for certain products. Speaking at a Mo

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investo...

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early

The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.